Nature Communications (Nov 2018)
RET rearrangements are actionable alterations in breast cancer
- Bhavna S. Paratala,
- Jon H. Chung,
- Casey B. Williams,
- Bahar Yilmazel,
- Whitney Petrosky,
- Kirstin Williams,
- Alexa B. Schrock,
- Laurie M. Gay,
- Ellen Lee,
- Sonia C. Dolfi,
- Kien Pham,
- Stephanie Lin,
- Ming Yao,
- Atul Kulkarni,
- Frances DiClemente,
- Chen Liu,
- Lorna Rodriguez-Rodriguez,
- Shridar Ganesan,
- Jeffrey S. Ross,
- Siraj M. Ali,
- Brian Leyland-Jones,
- Kim M. Hirshfield
Affiliations
- Bhavna S. Paratala
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Jon H. Chung
- Foundation Medicine
- Casey B. Williams
- Avera Cancer Institute Center for Precision Oncology
- Bahar Yilmazel
- Foundation Medicine
- Whitney Petrosky
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Kirstin Williams
- Avera Cancer Institute Center for Precision Oncology
- Alexa B. Schrock
- Foundation Medicine
- Laurie M. Gay
- Foundation Medicine
- Ellen Lee
- University Radiology Group
- Sonia C. Dolfi
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Kien Pham
- Department of Pathology and Laboratory Medicine, Rutgers New Jersey Medical School and Rutgers Robert Wood Johnson Medical School
- Stephanie Lin
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Ming Yao
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Atul Kulkarni
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Frances DiClemente
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Chen Liu
- Department of Pathology and Laboratory Medicine, Rutgers New Jersey Medical School and Rutgers Robert Wood Johnson Medical School
- Lorna Rodriguez-Rodriguez
- Rutgers University
- Shridar Ganesan
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- Jeffrey S. Ross
- Foundation Medicine
- Siraj M. Ali
- Foundation Medicine
- Brian Leyland-Jones
- Avera Cancer Institute Center for Precision Oncology
- Kim M. Hirshfield
- Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
- DOI
- https://doi.org/10.1038/s41467-018-07341-4
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Fusions of the gene RET have been described in thyroid and lung cancers. Here, the AUs identify RET gene alterations, including known fusions, novel fusions, and rearrangements in breast cancer (BC) that are involved in the tumorigenic process and show the benefit of RET therapy in a recurrent BC patient carrying the NCOA4-RET fusion.
